focus -WSS

focus

author：knowledge 2025-10-01 00:06:16 - browse：95

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Amazon expands telehealth clinic nationwide

explore

Wikipedia

WSS

When a patient nears the end, a feared therapy can comfort

EQRx, failed developer of low

Micronoma's microbiome cancer diagnostic approach under fire

Sanders wants to replace patents with prizes for drug inventions

There’s a way to spot data fakery. All journals should be using it

Extensive review finds private equity owners jack up cost of care

Wikipedia

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The high cost of giving birth even with insurance

NIH launches clinical trials and new research office for long Covid

Medical leaders decry Supreme Court decision on affirmative action

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Activists slam private health insurers over coverage restrictions

Trump indictment: Who are the 'co

ChatGPT in medicine: STAT answers readers' burning questions

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Anesthesiologist group: stop taking Ozempic before surgery

There’s a way to spot data fakery. All journals should be using it

Wikipedia

'CMA Fest' 2023: How to watch, who is performing and more

National panel will explore requiring free Covid tests

Mystery swirls around US soldier who entered North Korea days ago, officials say

What to expect as Trump is arraigned on his Jan 6. indictment

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

Extensive review finds private equity owners jack up cost of care

explore

explore

Wikipedia

explore